Your browser doesn't support javascript.
loading
PARP9-DTX3L ubiquitin ligase targets host histone H2BJ and viral 3C protease to enhance interferon signaling and control viral infection.
Zhang, Yong; Mao, Dailing; Roswit, William T; Jin, Xiaohua; Patel, Anand C; Patel, Dhara A; Agapov, Eugene; Wang, Zhepeng; Tidwell, Rose M; Atkinson, Jeffrey J; Huang, Guangming; McCarthy, Ronald; Yu, Jinsheng; Yun, Nadezhda E; Paessler, Slobodan; Lawson, T Glen; Omattage, Natalie S; Brett, Tom J; Holtzman, Michael J.
Afiliação
  • Zhang Y; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Mao D; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Roswit WT; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Jin X; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Patel AC; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Patel DA; Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Agapov E; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Wang Z; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Tidwell RM; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Atkinson JJ; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Huang G; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • McCarthy R; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Yu J; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Yun NE; Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Paessler S; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
  • Lawson TG; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
  • Omattage NS; Department of Chemistry, Bates College, Lewiston, Maine, USA.
  • Brett TJ; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Holtzman MJ; Drug Discovery Program, Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Nat Immunol ; 16(12): 1215-27, 2015 Dec.
Article em En | MEDLINE | ID: mdl-26479788
ABSTRACT
Enhancing the response to interferon could offer an immunological advantage to the host. In support of this concept, we used a modified form of the transcription factor STAT1 to achieve hyper-responsiveness to interferon without toxicity and markedly improve antiviral function in transgenic mice and transduced human cells. We found that the improvement depended on expression of a PARP9-DTX3L complex with distinct domains for interaction with STAT1 and for activity as an E3 ubiquitin ligase that acted on host histone H2BJ to promote interferon-stimulated gene expression and on viral 3C proteases to degrade these proteases via the immunoproteasome. Thus, PARP9-DTX3L acted on host and pathogen to achieve a double layer of immunity within a safe reserve in the interferon signaling pathway.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Virais / Cisteína Endopeptidases / Histonas / Poli(ADP-Ribose) Polimerases / Ubiquitina-Proteína Ligases Limite: Animals / Humans Idioma: En Revista: Nat Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Virais / Cisteína Endopeptidases / Histonas / Poli(ADP-Ribose) Polimerases / Ubiquitina-Proteína Ligases Limite: Animals / Humans Idioma: En Revista: Nat Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos